Primary prostate cancer (PCa) development is predominantly driven by androgens acting through its cognate binding partner, the androgen receptor (AR) [1], and consequently led to the use of androgen-deprivation therapy (ADT) as the standard care regimen for PCa [2]. The gene discussed is AR; the disease is posterior cortical atrophy.